STOP-GAP : A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Skin<br/>CancersCancer LocationSkin
Cancers

Systemic therapy | SkinMelanoma (Skin)

Trial Overview Read MoreRead more

This phase III trial is comparing the effectiveness of giving immunotherapy (PD-1 inhibitors) intermittently as opposed to continuously, for the treatment of metastatic melanoma.
 

This trial is treating patients with Metastatic Melanoma.

This is a systemic trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Cooperative Group

Canadian Cancer Trials Group

Other Non-Commercial Sponsor

Melanoma and Skin Cancer Trials Limited

Summary

Patients eligible to participate in this study will receive a government funded PD-1 inhibitor either administered continuously, or intermittently.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Medical Oncology
Prahran
Ms Kate Sinn
K.Sinn@alfred.org.au
03 90760569

Monash Health, Medical Oncology
Clayton
Lung and Head & Neck Research Study Coordinator
lung.oncresearch@monashhealth.org
0417607146

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next